Swedbank AB Sells 1,858 Shares of Bio-Rad Laboratories, Inc. $BIO

Swedbank AB reduced its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 38.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,002 shares of the medical research company’s stock after selling 1,858 shares during the period. Swedbank AB’s holdings in Bio-Rad Laboratories were worth $731,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Quarry LP bought a new position in Bio-Rad Laboratories during the 1st quarter worth $29,000. Curat Global LLC bought a new position in shares of Bio-Rad Laboratories in the 1st quarter worth about $34,000. Allworth Financial LP raised its position in shares of Bio-Rad Laboratories by 260.0% in the 1st quarter. Allworth Financial LP now owns 144 shares of the medical research company’s stock worth $36,000 after acquiring an additional 104 shares in the last quarter. Headlands Technologies LLC raised its position in shares of Bio-Rad Laboratories by 64.1% in the 1st quarter. Headlands Technologies LLC now owns 356 shares of the medical research company’s stock worth $87,000 after acquiring an additional 139 shares in the last quarter. Finally, Twin Tree Management LP bought a new position in shares of Bio-Rad Laboratories in the 1st quarter worth about $87,000. 65.24% of the stock is owned by institutional investors.

Analyst Ratings Changes

BIO has been the subject of several research analyst reports. Wells Fargo & Company lifted their price objective on Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. Wall Street Zen lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, August 22nd. Royal Bank Of Canada lifted their price objective on Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an “outperform” rating in a research report on Friday, August 1st. Finally, Zacks Research raised Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 26th. Three research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $333.50.

Bio-Rad Laboratories Price Performance

BIO stock opened at $282.21 on Wednesday. Bio-Rad Laboratories, Inc. has a 52-week low of $211.43 and a 52-week high of $387.99. The business has a 50-day simple moving average of $273.61 and a two-hundred day simple moving average of $252.13. The company has a market capitalization of $7.64 billion, a P/E ratio of 24.06 and a beta of 0.95. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.67 and a current ratio of 5.12.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share for the quarter, topping analysts’ consensus estimates of $1.93 by $0.68. Bio-Rad Laboratories had a return on equity of 4.01% and a net margin of 12.50%.The firm had revenue of $651.60 million for the quarter, compared to the consensus estimate of $614.82 million. During the same quarter in the previous year, the business earned $3.11 EPS. The company’s revenue was up 2.1% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. Research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.